Department of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
Curr Opin Urol. 2012 Jan;22(1):61-5. doi: 10.1097/MOU.0b013e32834d543f.
With the expanding use of new technology in the treatment of clinically localized prostate cancer (PCa), the financial burden on the healthcare system and the individual has been important. Robotics offer many potential advantages to the surgeon and the patient. We assessed the potential cost-effectiveness of robotics in urological surgery and performed a comparative cost analysis with respect to other potential treatment modalities.
The direct and indirect costs of purchasing, maintaining, and operating the robot must be compared to alternatives in treatment of localized PCa. Some expanding technologies including intensity-modulated radiation therapy are significantly more expensive than robotic surgery. Furthermore, the benefits of robotics including decreased length of stay and return to work are considerable and must be measured when evaluating its cost-effectiveness.
Robot-assisted laparoscopic surgery comes at a high cost but can become cost-effective in mostly high-volume centers with high-volume surgeons. The device when utilized to its maximum potential and with eventual market-driven competition can become affordable.
随着新技术在治疗局限性前列腺癌（PCa）中的应用不断扩大，医疗保健系统和个人的经济负担变得很重要。机器人技术为外科医生和患者提供了许多潜在的优势。我们评估了机器人技术在泌尿外科手术中的潜在成本效益，并针对其他潜在治疗方式进行了比较成本分析。
购买、维护和操作机器人的直接和间接成本必须与治疗局限性 PCa 的替代方法进行比较。一些扩展技术，包括强度调制放射治疗，比机器人手术昂贵得多。此外，机器人技术的优势，包括缩短住院时间和恢复工作，是相当可观的，在评估其成本效益时必须加以衡量。
机器人辅助腹腔镜手术的成本很高，但在高容量中心和高容量外科医生中，它可能具有成本效益。该设备在充分发挥其潜力并最终受到市场驱动竞争的情况下，可以负担得起。
